Skip to content
AnalystLens

West Pharmaceutical Services 8-K Report, Financial Results (Jul 25, 2024)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed July 25, 2024
Period End
July 25, 2024
Security
WST
In the record · 2016–202610-K1110-Q338-K118

WST filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Feb ’18Feb ’18
  2. Leadership change8-K · May ’20May ’20
  3. Leadership change8-K · Jul ’22Jul ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed July 25, 2024. Cited figures are marked; the original filing is the authoritative source.

West Pharmaceutical Services, Inc. (NYSE: WST) reported second-quarter 2024 net sales of $702.1 milliona, a decline of 6.9%, with organic net sales down 5.9%.

Reported-diluted EPS was $1.51b versus $2.06 a year earlier, and adjusted-diluted EPS was $1.52 versus $2.11. Management attributed the weakness to an elevated level of customer destocking, noting that second-quarter revenues increased sequentially. The Proprietary Products segment's net sales declined 9.4% to $559.7 million, while the Contract-Manufactured Products segment grew 4.9% to $142.4 million.

The company materially lowered its full-year 2024 outlook. Net sales guidance was cut to $2.870 billion to $2.900 billionc from $3.000 billion to $3.025 billion, with organic net sales now expected to decline approximately 1% to 2%. Adjusted-diluted EPS guidance was reduced to $6.35 to $6.65 from $7.63 to $7.88, although the range includes $0.22 of first-half tax benefits from stock-based compensation.

Full-year capital spending was raised to $375 milliond from $350 million. Cash generation weakened in the first half of 2024: operating cash flow was $283.2 million, down 7.8%, and free cash flow fell to $92.4 million, down 38.3%. Management said it remains confident in a return to organic growth in the fourth quarter and into 2025, based on its confirmed order book, though the company repurchased $454.1 million of shares in the first half.

02—Key points

Key Highlights

  1. Second-quarter net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%.
  2. Reported-diluted EPS was $1.51 versus $2.06 a year earlier; adjusted-diluted EPS was $1.52 versus $2.11.
  3. Full-year 2024 net sales guidance lowered to $2.870 billion–$2.900 billion from $3.000 billion–$3.025 billion; organic net sales now expected to decline approximately 1% to 2%.
  4. Full-year 2024 adjusted-diluted EPS guidance cut to $6.35–$6.65 from $7.63–$7.88, including $0.22 of first-half stock-based compensation tax benefits.
  5. Proprietary Products net sales fell 9.4% to $559.7 million, while Contract-Manufactured Products grew 4.9% to $142.4 million.
  6. First-half operating cash flow was $283.2 million, down 7.8%, and free cash flow was $92.4 million, down 38.3%.
  7. Full-year 2024 capital spending guidance raised to $375 million from $350 million.

03—Questions

Frequently Asked Questions

  1. Why did West Pharmaceutical lower its 2024 guidance?

    Management said second-quarter results were impacted by an elevated level of customer destocking and were below its expectations. The updated net sales range of $2.870 billion to $2.900 billion reflects this, with organic net sales now expected to decline approximately 1% to 2%.

  2. Is the company expecting a recovery in organic growth?

    Management said it expects second-half revenues to be stronger than the first half and remains confident in a return to organic growth in the fourth quarter and as it moves into 2025, based on its confirmed order book and ongoing customer conversations.

  3. How did cash flow and capital spending change?

    For the first six months of 2024, operating cash flow was $283.2 million, down 7.8%, and capital expenditures were $190.8 million, up 21.1%. Free cash flow was $92.4 million, down 38.3%. Full-year capital spending is now expected to be $375 million, up from $350 million.

  4. Does the EPS guidance include one-time benefits?

    Yes. The updated adjusted-diluted EPS range of $6.35 to $6.65 includes $0.22 of EPS from first-half 2024 tax benefits tied to stock-based compensation. The company does not forecast such benefits for future periods, so any additional benefits would be a positive adjustment.

04—Continue

← View all 8-K filings